Here's a classic biotech puzzle: you have a promising drug candidate for a huge market, but running clinical trials is incredibly expensive and slow. Do you stick with the original, comprehensive plan, or do you get creative to save time and money? Medicus Pharma Ltd. (MDCX) is choosing the latter.

The company said Monday it has submitted an "optimized" Phase 2 study design to the FDA for its drug Teverelix. The target is benign prostatic hyperplasia, or BPH—that's an enlarged prostate—and specifically preventing the painful complication where you suddenly can't urinate. It's a problem for a lot of men, and Medicus sees it as a $2 billion market opportunity. The new plan is basically a leaner, meaner version of the old one, built to get answers faster without breaking the bank.

Think of it this way: instead of a massive, years-long study aimed at proving everything at once, they're running a tighter, more focused experiment. The revised trial, called ANT-2111-02, will enroll about 126 patients. That's roughly one-third the size of the earlier plan. The main goal is to see a clear "pharmacodynamic signal"—fancy science talk for early evidence the drug is doing what it's supposed to do. In this case, that means reducing prostate volume.

Why shrink the study? The company says it's a "data-driven shift" that will lower development costs and improve "execution speed and operational efficiency." In plain English: it should cost less and finish quicker. This isn't just about saving cash; it's about strategy. Management noted that getting clinical data more quickly could support "earlier strategic discussions, including potential partnering opportunities." Translation: positive results from a smaller, faster trial could make the company a more attractive investment or acquisition target sooner rather than later.

So, what does the actual trial look like? It's a randomized, double-blind, single-dose study. Patients will be split into four groups. Some will get a 90 mg dose of Teverelix via an intramuscular injection. Others will get a 120 mg dose subcutaneously (under the skin). The remaining groups will get placebo shots. Everyone gets just one dose on Day 1 and will continue their standard alpha-blocker therapy. The whole thing runs for 52 weeks: a 28-week treatment period followed by 24 weeks of follow-up to see how long the effects last.

The primary thing they're measuring is the percentage change in total prostate volume at Week 12. If the prostate shrinks significantly compared to placebo, that's the early win they're looking for. They'll also track secondary stuff like urine flow rate, how much urine is left in the bladder after going, and whether the painful urinary retention comes back.

Here's another smart move: they've planned an interim analysis. Once about half the patients have completed that crucial 12-week assessment, they'll peek at the data. This early look should help them decide which dose and administration method (the shot in the muscle or under the skin) works best, and it will inform the design of a potential larger Phase 3 study down the road.

It's a calculated gamble. A smaller study carries more statistical risk, but if the drug effect is strong, they'll see it clearly and save a ton of time and money. If it works, they get to the multi-billion-dollar market faster. If it doesn't, they find out sooner and can cut their losses. In the high-stakes world of drug development, sometimes the smartest play is to design a trial that gives you a clear yes-or-no answer as efficiently as possible.

Investors were weighing the news Monday morning. Medicus Pharma shares were down 4.92% at $0.43 in premarket trading, according to market data.